Landscapes / Targets
CTLA-4
25 drugs act on CTLA-4, in 140 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs25
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
PD-1/CTLA-4 bispecific antibody |
Akeso · Public 9926.HK |
Approved in China | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | A cancer drug that hits three targets | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma and 23 more | ||||
| Open drug page | |||||
CTLA-4 antibody |
AstraZeneca · Public AZN |
Approved | 30 Nov 2026soonPhase 2 trial completes | ||
| How it works | A cancer drug that hits three targets | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Unresectable Pleural or Peritoneal Malignant Mesothelioma and 15 more | ||||
| Open drug page | |||||
CTLA-4 antibody |
Bristol Myers Squibb · Public BMY |
Approved | 5 Feb 2027Phase 2 trial completes | ||
| How it works | A cancer drug that hits three targets | ||||
| Next date | 5 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Renal Cell Carcinoma, Solid Tumor and 16 more | ||||
| Open drug page | |||||
— |
Approved in China | Jun 2027Phase 1/2 trial completes | |||
| Next date | Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Carcinoma, Non-Small-Cell Lung and 8 more | ||||
| Open drug page | |||||
— |
Innovent · Public 1801.HK |
Approved in China | 31 Dec 2027Phase 2/3 trial completes | ||
| Next date | 31 Dec 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma (HCC) | ||||
| Open drug page | |||||
CTLA-4 antibody |
OncoC4 +1 · Public BNTX |
Phase 3 | 30 Nov 2026soonPhase 1/2 trial completes | ||
| How it works | A cancer drug that hits three targets | ||||
| Next date | 30 Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Non Small Cell Lung Cancer, Advanced Solid Tumor and 22 more | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 3 | 30 Dec 2026Phase 2 trial completes | ||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Biliary Tract Cancer, Advanced Hepatocellular Carcinoma and 12 more | ||||
| Open drug page | |||||
— |
Phase 3 | Jan 2027Phase 3 trial completes | |||
| Next date | Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Melanoma (Skin), Melanoma Stage III and 5 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | Apr 2027Phase 2/3 trial completes | |||
| Next date | Apr 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Amyotrophic Lateral Sclerosis (ALS) | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
AstraZeneca · Public AZN |
Phase 3 | 4 May 2027Phase 2 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 4 May 2027 · Phase 2 trial completes | ||||
| Also tested for | Gastric Cancer, Non-small Cell Lung Cancer and 23 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | 1 Dec 2027Phase 2 trial completes | |||
| Next date | 1 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Cancer, Hepatocellular Carcinoma and 2 more | ||||
| Open drug page | |||||
— |
Junshi Biosciences · Public 1877.HK |
Phase 3 | 31 Dec 2027Phase 2 trial completes | ||
| Next date | 31 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma | ||||
| Open drug page | |||||
— |
Phase 2 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumor, Non-small Cell Lung Cancer and 10 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Dec 2026Phase 2 trial completes | |||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor Cancer, Advanced Solid Tumor and 1 more | ||||
| Open drug page | |||||
PD-1/VEGF/CTLA-4 trispecific antibody |
CStone · Public 2616.HK |
Phase 1/2 | Dec 2026First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan) | ||
| How it works | A cancer drug that hits three targets | ||||
| Next date | Dec 2026 · First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan) · press release | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Jun 2027Phase 1/2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced/Metastatic Solid Tumors | ||||
| Open drug page | |||||
— |
Roche · Public ROG.SW |
Phase 1/2 | 30 Jul 2027Phase 1/2 trial completes | ||
| Next date | 30 Jul 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Liver Cancers | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 2 | Jul 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma and 9 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 2 | Sep 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Cancer, Angiosarcoma and 7 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 2 | — | |||
| How it works | An antibody | ||||
| Also tested for | Ovarian Cancer, Clear Cell Carcinoma and 3 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 25 of 25 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026